Can oligodendrocyte precursor cells be a therapeutic target for mitigating cognitive decline in cerebrovascular disease?

J Cereb Blood Flow Metab. 2020 Aug;40(8):1735-1736. doi: 10.1177/0271678X20929432.

Abstract

Oligodendrocyte precursor cells (OPCs) give rise to mature myelin-forming oligodendrocytes during white matter development. In adult brains, some populations of OPCs remain to renew oligodendrocyte pools and myelin. Two recent studies highlight the importance of OPCs in white matter homeostasis. Genetic tracing studies suggest that age-related decline in OPCs may contribute to diminished myelin renewal and memory deficits in mouse models. Single cell transcriptomics and imaging may now define specific subsets of OPCs involved in process elaboration, motility and myelination. These advances raise the possibility of pursuing OPCs as novel therapeutic targets for vascular cognitive impairment.

Keywords: Oligodendrocyte precursor cell; aging; heterogeneity; stroke recovery; white matter.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aging / drug effects*
  • Aging / pathology
  • Animals
  • Cerebrovascular Disorders / drug therapy*
  • Cognitive Dysfunction / prevention & control*
  • Humans
  • Myelin Sheath / pathology
  • Oligodendrocyte Precursor Cells / drug effects*
  • Oligodendrocyte Precursor Cells / pathology
  • Oligodendroglia / drug effects*
  • Oligodendroglia / pathology
  • White Matter / drug effects*
  • White Matter / pathology